CN1046723C - 四环化合物、含有它们的药物组合物及其用途 - Google Patents

四环化合物、含有它们的药物组合物及其用途 Download PDF

Info

Publication number
CN1046723C
CN1046723C CN94192241A CN94192241A CN1046723C CN 1046723 C CN1046723 C CN 1046723C CN 94192241 A CN94192241 A CN 94192241A CN 94192241 A CN94192241 A CN 94192241A CN 1046723 C CN1046723 C CN 1046723C
Authority
CN
China
Prior art keywords
trans
hexahydro
phenanthrene
aza
thia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN94192241A
Other languages
English (en)
Chinese (zh)
Other versions
CN1124489A (zh
Inventor
M·R·米克里迪斯
Y·-F·洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1124489A publication Critical patent/CN1124489A/zh
Application granted granted Critical
Publication of CN1046723C publication Critical patent/CN1046723C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN94192241A 1993-04-06 1994-03-18 四环化合物、含有它们的药物组合物及其用途 Expired - Lifetime CN1046723C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4342493A 1993-04-06 1993-04-06
US08/043,424 1993-04-06
US20998294A 1994-03-17 1994-03-17
US08/209,982 1994-03-17

Publications (2)

Publication Number Publication Date
CN1124489A CN1124489A (zh) 1996-06-12
CN1046723C true CN1046723C (zh) 1999-11-24

Family

ID=26720416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94192241A Expired - Lifetime CN1046723C (zh) 1993-04-06 1994-03-18 四环化合物、含有它们的药物组合物及其用途

Country Status (15)

Country Link
US (1) US5597832A (de)
EP (1) EP0690863B1 (de)
JP (1) JP2710695B2 (de)
KR (1) KR100383342B1 (de)
CN (1) CN1046723C (de)
AT (1) ATE233765T1 (de)
AU (1) AU677842B2 (de)
BR (1) BR9405972A (de)
DE (1) DE69432217T2 (de)
DK (1) DK0690863T3 (de)
ES (1) ES2193158T3 (de)
FI (1) FI954738L (de)
NO (1) NO311762B1 (de)
PT (1) PT690863E (de)
WO (1) WO1994022858A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103387583A (zh) * 2012-05-09 2013-11-13 中国科学院上海药物研究所 二芳基并[a,g]喹嗪类化合物、其制备方法、药物组合物及其应用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659037A (en) * 1994-08-18 1997-08-19 Abbott Laboratories Process for preparing chiral tetracyclic dopaminergic compounds
JP3036847B2 (ja) 1995-01-13 2000-04-24 サマーセット・ファーマシューティカルズ・インコーポレイテッド デスメチルセレギリンを用いる方法および医薬組成物
WO1996025411A1 (en) 1995-02-15 1996-08-22 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
US5668141A (en) * 1996-04-02 1997-09-16 Abbott Laboratories Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
AU750808B2 (en) 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US5969159A (en) * 1999-02-16 1999-10-19 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone tiletamine and tiletamine acid addition salts such as tiletamine hydrochloride
US6147226A (en) * 1999-02-16 2000-11-14 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone, tiletamine and tiletamine acid addition salts, such as tiletamine hydrochloride
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
AU2001283393B2 (en) * 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AU2003217430B2 (en) * 2002-02-15 2008-10-23 Darpharma, Inc. Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2005055920A2 (en) * 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Compositions and methods for treatment of psychiatric disorders
CN1964713A (zh) * 2003-12-23 2007-05-16 达法尔摩公司 多巴胺－受体结合化合物的共同使用
EP2010541A2 (de) * 2006-02-21 2009-01-07 Purdue Research Foundation Übertragene chromenoisochinoline, synthese und anwendungsverfahren
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
US9567316B2 (en) 2012-03-07 2017-02-14 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
RU2537170C1 (ru) * 2013-11-20 2014-12-27 Войсковая Часть 41598 Средство профилактики церебральной формы острой лучевой болезни
WO2026043936A1 (en) * 2024-08-20 2026-02-26 Universidad Del Desarrollo Cysteine-bound short-chain fatty acid derivatives for the treatment of addictions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2691024A (en) * 1952-05-26 1954-10-05 Schenley Ind Inc Dihydropyrrolo-(3.2-c) quinoline derivatives
US3541100A (en) * 1967-12-14 1970-11-17 American Cyanamid Co Benzheteroazolo(2,3-a)isoquinolium salts
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3943137A (en) * 1973-07-09 1976-03-09 University Of Kansas Endowment Association Acronycine derivatives
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
DE69334206D1 (de) * 1992-05-26 2008-04-03 Purdue Research Foundation Substituierte hexahydrobenzo(a) phenanthridine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103387583A (zh) * 2012-05-09 2013-11-13 中国科学院上海药物研究所 二芳基并[a,g]喹嗪类化合物、其制备方法、药物组合物及其应用

Also Published As

Publication number Publication date
CN1124489A (zh) 1996-06-12
BR9405972A (pt) 1995-12-12
AU677842B2 (en) 1997-05-08
JP2710695B2 (ja) 1998-02-10
DE69432217D1 (de) 2003-04-10
NO953957L (no) 1995-11-21
EP0690863B1 (de) 2003-03-05
NO953957D0 (no) 1995-10-05
FI954738A7 (fi) 1995-12-05
WO1994022858A1 (en) 1994-10-13
ATE233765T1 (de) 2003-03-15
FI954738L (fi) 1995-12-05
EP0690863A4 (de) 1995-11-07
ES2193158T3 (es) 2003-11-01
JPH08508487A (ja) 1996-09-10
KR100383342B1 (ko) 2003-08-25
DE69432217T2 (de) 2004-04-08
PT690863E (pt) 2003-07-31
KR960701870A (ko) 1996-03-28
AU6520394A (en) 1994-10-24
EP0690863A1 (de) 1996-01-10
DK0690863T3 (da) 2003-06-30
US5597832A (en) 1997-01-28
NO311762B1 (no) 2002-01-21
FI954738A0 (fi) 1995-10-05

Similar Documents

Publication Publication Date Title
CN1124489A (zh) 作为多巴胺激动剂的四环化合物
CN1157392C (zh) 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物
CN100345847C (zh) 新的联芳基甲酰胺
CN1249051C (zh) 毒蕈碱性激动剂
CN1703403A (zh) 趋代谢的谷氨酸盐受体拮抗剂
CN1290251A (zh) N－酰基环胺衍生物
CN1361779A (zh) 新化合物
CN1058405A (zh) 奎宁环衍生物
CN1432011A (zh) 含有苯并酰胺哌啶的化合物及相关的化合物
CN1571787A (zh) 奎宁环衍生物、制备它们的方法和它们作为m2和/或m3毒蕈碱受体抑制剂的用途
CN101061097A (zh) 新的γ分泌酶抑制剂
CN1060285A (zh) 含氮非芳香杂环的稠环类似物
CN101076532A (zh) 作为甘氨酸转运体I(GlyT－1)抑制剂用于治疗阿尔茨海默氏病的二环和三环取代的苯甲酮化合物
CN1471536A (zh) 趋化因子受体拮抗剂及其使用方法
CN1178922C (zh) 取代的1-氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1839135A (zh) 三环δ阿片样物质调节剂
CN1295563A (zh) 用作毒蕈碱性受体拮抗剂的2－芳基乙基－(哌啶－4－基甲基)胺衍生物
CN1045583A (zh) 四氢苯并咪唑衍生物
CN101068595A (zh) Cgrp受体拮抗剂
CN1067892A (zh) 新的吡咯并[2，3-b]吡啶衍生物的制备方法
CN1305477A (zh) 氮杂双环5－ht1受体配体
CN1016871B (zh) 二环和三环吡啶衍生物的制备方法
CN1289479C (zh) 作为5－ht1d受体配位体的5－环吲哚化合物
CN1130365C (zh) α－1肾上腺素能化合物,含有该化合物的药物组合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ABBOTT PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: ABBOTT LAB

CP01 Change in the name or title of a patent holder

Address after: Illinois State

Patentee after: ABBOTT LABORATORIES

Address before: Illinois State

Patentee before: ABBOTT LABORATORIES

ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130618

Address after: Illinois State

Patentee after: ABBVIE

Address before: Illinois State

Patentee before: ABBOTT LABORATORIES

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20140318

Granted publication date: 19991124